Telomerase inhibition, telomere shortening, and cellular uptake of the perylene derivatives PM2 and PIPER in prostate cancer cells

• Main Authors: Navakoon Kaewtunjai, Ratasark Summart, Ariyaphong Wongnoppavich, Bannakij Lojanapiwat, T. Randall Lee, Wirote Tuntiwechapikul
• Format: Journal
• Published: 2019
• Subjects: Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067087489&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/65862
• Institution: Chiang Mai University

© 2019 The Pharmaceutical Society of Japan. Prostate cancer is the second most common cancer among men worldwide, and it is ranked first in the United States and Europe. Since prostate cancer is slow-growing, active surveillance for low-risk cancer has been increasingly supported by various guidelines. Most prostate cancers reactivate telomerase to circumvent the replicative senescence caused by the end replication problem; therefore, telomerase inhibition is potentially useful for the suppression of prostate cancer progression during this active surveillance or for the prevention of cancer recurrence after conventional therapies. In this study, we demonstrated that the perylene derivatives, PM2 and PIPER, could suppress human telomerase reverse transcriptase (hTERT) expression and telomerase activity in the short-term treatment of androgen-dependent prostate cancer cell line LNCaP and the androgen-independent prostate cancer cell line PC3 prostate cancer cells. Long-term treatment with subcytotoxic doses of these compounds in both prostate cancer cells showed telomere shortening and a significant increase in senescent cells. Although the acute cytotoxicity of PM2 was about 30 times higher than that of PIPER in both prostate cancer cells, the cellular uptake of both compounds was comparable as determined by flow cytometry and fluorescent microscopy.